100g

Riboflavin, USP

Ribonucleic Acid

ROR1 (Receptor tyrosine kinase-like orphan receptor 1), also known as neurotrophic tyrosine kinase receptor-related 1 (NTRKR1), is a member of the ROR family within the receptor tyrosine kinases (RTK) superfamily. Two ROR family members (ROR1 and ROR2) have been identified and are characterized by the intracellular tyrosine kinase domains, highly related to those of the Trk-family receptor tyrosine kinases, and by the extracellular Frizzled-like cysteine-rich domains and kringle domains, which are common to receptors of the Wnt family members.

Rose Hips, Extract, 4:1, Powder

RRR-Vitamin E Succinate, 1 mg = 0.81 alpha-tocopherol equivalents, USP

Rubidium Chloride, High Purity

Rubidium Sulfate

Rutin, Powder

S-(+)-Mandelic Acid

S-Carboxymethyl-L-cysteine

Saccharin Sodium, Dihydrate, Crystalline, USP

Saccharin Sodium, Dihydrate, Powder, USP

Safranine O

Salcomine, [=N,N’-Bis(salicylidene)ethylenediiminocobalt(II)]

Salicin

Salicylaldehyde

Salicylaldoxime

Sarcosine

Sarcosine, Ultrapure

GenScript SARS-CoV-2 ADE-Causing Antibody (S9HC) reacts with SARS-CoV-2 Spike protein of wild type and delta variant. It can obviously enhance the SARS-COV-2 binding with ACE2.

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and Variants of Concern (VOC) including Alpha, Beta, Delta, and Omicron. Reactivity with Gamma variant has not been tested.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is the most abundant structural protein of the coronavirus which is associated with the nucleic acid. The sublineage B.1.617.2 has been redesignated as a “variant of concern” (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.

SARS-CoV-2 Spike (484Q) Antibody (Q8), mAb, Mouse is specific for 484Q site of B.1.617 SARS-CoV-2. This product can recognize single mutant (E484Q) and double mutant (L452R, E484Q), but can not recognize the wild type and single mutant (L452R).

The product is specific for E484 site of wild-type RBD.For specific mutant protein, the product recognizes wild-type RBD, RBD single mutant (N501Y), and RBD single mutant (K417N), but not recognizes RBD single mutant (E484K) and RBD triple mutant (K417N, E484K and N501Y), as seen in Figure 2.

The product is specific for N501 site of wild-type RBD.For specific mutant protein, the product recognizes wild-type RBD, RBD single mutant (E484K), and RBD single mutant (K417N), but not recognizes RBD single mutant (N501Y) and RBD triple mutant (K417N, E484K and N501Y), as seen in Figure 2.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. ECD is the extra cellular domain of spike protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag) carries a Avi Tag followed by a polyhistidine tag at the C-terminus. It has high binding affinity to human chimeric ACE2.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as “variant of concern” (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The spike protein mutation N501Y is one of six key contact residues within the receptor-binding domain (RBD) and has been identified as increasing binding affinity to human and murine ACE2.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. The spike protein mutation D614G became dominant during the globally pandemic. The D614G mutation enhances its replication ability in upper respiratory tract, transmission ability and viral loads in the patients’ lung epithelial cells. It may also affect vaccine efficacy and antibody therapy.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. S protein plays an important role in the induction of neutralizing antibodies and T-cell responses, as well as protective immunity.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. S protein plays an important role in the induction of neutralizing antibodies and T-cell responses, as well as protective immunity.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as “variant of concern” (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.